Nasal Spray Flu Vaccine, FluMist, Now Available for At-Home Use
By I. Edwards HealthDay Reporter
TUESDAY, Aug. 19, 2025 — For the first time, people can get their annual flu vaccine without leaving the comfort of home.
FluMist, a nasal spray flu vaccine made by AstraZeneca, is now available for at-home use through a service called FluMist Home, the company announced.
The U.S. Food and Drug Administration (FDA) first approved FluMist in 2003 for use in doctors’ offices and pharmacies. Last year, the FDA expanded approval, making it the first flu vaccine that can be self-administered, CBS News said.
FluMist Home allows customers to order the same nasal spray available at clinics, shipped directly to their homes. It will be offered in 34 states during the 2025-2026 flu season.
The cost of FluMist is covered by most commercial insurance, though there is an $8.99 shipping and processing fee, according to the online ordering platform.
To order, customers provide personal information, medical history, insurance details and a payment.
FluMist is approved for people ages 2 to 49. Caregivers should administer the vaccine to children ages 2 to 17, according to the FDA.
The vaccine should not be used in people with severe allergies to its ingredients, eggs or other flu vaccines, according to the company.
Full safety information and administration instructions are provided on the product website.
FluMist Home will launch in these states for the 2025-26 flu season:
-
Alabama
-
Arizona
-
California
-
Colorado
-
Connecticut
-
Florida
-
Georgia
-
Iowa
-
Idaho
-
Illinois
-
Massachusetts
-
Maryland
-
Maine
-
Michigan
-
Montana
-
North Carolina
-
North Dakota
-
Nebraska
-
New Hampshire
-
New Jersey
-
Nevada
-
Ohio
-
Oregon
-
Pennsylvania
-
South Carolina
-
South Dakota
-
Tennessee
-
Texas
-
Utah
-
Virginia
-
Vermont
-
Washington
-
Wisconsin
-
Wyoming
The company noted that local pharmacy laws prevent it from being available everywhere.
Sources
- CBS News, Aug. 15, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
FDA Approves Sublingual, Nonopioid Daily Treatment for Fibromyalgia, Tonmya
WEDNESDAY, Aug. 20, 2025 -- The U.S. Food and Drug Administration has approved Tonmya (cyclobenzaprine hydrochloride) sublingual tablets for the treatment of fibromyalgia in...
Pesticide Linked To Impaired Brain Development Among Kids
WEDNESDAY, Aug. 20, 2025 — Exposure to a common pesticide during pregnancy can impair children’s brain development and motor function for years to come, a new study...
COVID Can Prematurely Age Blood Vessels
WEDNESDAY, Aug. 20, 2025 — COVID-19 infection appears to cause women’s blood vessels to age prematurely, potentially increasing their risk of heart disease, a new...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.